阿德福韦酯联合拉米夫定治疗HBeAg阳性慢性乙型肝炎49例疗效观察

The observation of adefovir dipivoxi l in combination with lamivudine therapy for HBeAg positive chronic hepatitis B in 49 cases

目的探讨阿德福韦酯联合拉米夫定治疗HBeAg阳性慢性乙型肝炎初治患者的疗效。方法 49例HBeAg阳性初治患者给予阿德福韦酯口联合拉米夫定口服,观察ALT、HBeAg、HBVDNA的变化,共96周。结果在治疗12、24、48、96周时患者HBeAg血清转换率分别为10.20%、24.49%、32.65%和40.82%;HBVDNA转阴率分别为46.94%、65.31%、71.43%和81.63%;ALT复常率分别为48.98%、69.39%、73.47%和79.59%。结论初始阿德福韦酯联合拉米夫定治疗HBeAg阳性慢性乙型肝炎患者疗效满意,耐药率低。

Objective To investigate the efficacy of adefovir dipivoxil in combination with lamivudine therapy for HBeAg positive chronic hepatitis B. Methods Forty nine cases of HBeAg positive naive patients were given adefovir dipivoxil combined with lamivudine. The changes of ALT, HBeAg and HBVDNA in the patients were observed for 96 weeks. Results After 12 weeks, 24 weeks, 48 weeks and 96 weeks of treatment, HBeAg seroconversion rate were 10.20%, 24.49%, 32.65% and 40.82%; HBVDNA negative rate were 46.94%, 65.31%, 71.43% and 81.63%; ALT normalization rate were 48.98%, 69.39%, 73.47% and 79.59% respectively. Conclusion The results of initial adefovir dipivoxil combined with lamivudine treatment for HBeAg positive chronic hepatitis B patients is satisfactory, and drug resistance is low.